Science Sparks @ ACTREC
06th April 2026Publications
- 1. Noronha V, Sarkar L, Pillai A, Rao AR, Kumar A, Dhekale R, Mahajan S, Daptardar A, Sonkusare L, Vagal M, Mahajan P, Timmanpyati S, Gota V, Laskar S, Budrukar A, Swain M, Shetake A, Chowdhury OR, Pawar A, Prabhash K . Vulnerability assessment and decision-making in older patients with head and neck cancers planned for chemoradiation: Experience from a Tertiary Care Cancer Centre in India. Journal of Cancer Research and Therapeutics. 22(1):168-174
- 2. Chakrabarty N, Dadlani T, Mahajan A, Laskar SG, Nair D, Menon M, Rane S, Rane P, Deshmukh A, Pantvaidya G, Singh A, Sahu A, Patil A, Noronha V, Prabhash K, Chaturvedi P (2026). Diagnostic value of MRI-based iENE assessment for predicting major and minor extranodal extension in oral tongue carcinoma. Oral Oncology. 177:107960.
- 3. Ghag S, Jha AK, Konuparamban A, Puranik A, Rangarajan V(2026). A comparative analysis of OLINDA EXM 2.0 and MIRDcalc for Lu-177 DOTATATE radionuclide therapy, Radiation Physics and Chemistry. 245:113867.
Video of the Week
Early-Onset Breast Cancer: Insights From a Unique Patient Population
Upcoming Events
April 10-13, 2026
At Convocation Complex, University of Kashmir.
April 11, 2026
At ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai
April 17-19, 2026
At Tata Memorial Hospital, Parel
Do You Know?
In 2015, the FDA approved talimogene laherparepvec (T-VEC) for the treatment of some patients with metastatic melanoma that cannot be surgically removed.
Cancer News
News-Medical.Net, 31/03/2026
The team used LNPs to equip T cells to target fibroblast activation protein, or FAP, because it is present at high levels on a subset of cancer‑associated fibroblasts -cells known to be critical for PDAC progression...
MedicalXpress, 01/04/2026
To test the concept, the researchers placed the patch over melanoma cells cultured in the laboratory. They warmed the patch to 108 degrees Fahrenheit (42 degrees Celsius) with a low-power laser. In its now-activated state, the patch released copper ions into the melanoma cells directly beneath it...
Eurekalert, 01/04/2026
Patients with the RET fusion gene partners CCDC6 and KIF5B had high overall response rates to treatment. The median duration of response was longer in patients bearing CCDC6-RET (47.9 months) when compared to those with KIF5B-RET (13.1 months)...
© 2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)